EMD Serono presented data at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) conference, showcasing the sustained efficacy and safety of MAVENCLAD (cladribine) tablets in treating relapsing multiple sclerosis (RMS).

Studies have consistently demonstrated the efficacy of MAVENCLAD in reducing relapse rates and disease activity. Additional analyses now reveal its impact on neuroinflammation and disability progression.

MAGNIFY-MS sub-studies showed that MAVENCLAD significantly reduced disability accrual, including independent of relapse activity. Treatment-naïve patients experienced meager rates of progression.

Furthermore, MAVENCLAD has been shown to sustain benefits in cognition, MRI outcomes, and relapse prevention four years after treatment initiation. The CLARIFY-MS extension study supported this finding.

MAVENCLAD has maintained a consistent safety profile throughout clinical trials and real-world use. Two-year data from the MAGNIFY-MS study indicated low relapse rates and minimal disability progression.

These findings suggest that MAVENCLAD provides a sustained and durable effect in reducing disease activity and preserving physical abilities in individuals with RMS. It demonstrates the medication’s ability to impact neuroinflammation and prevent progression, highlighting its potential to improve long-term outcomes for patients living with multiple sclerosis.

Source link: http://www.businesswire.com/news/home/20240912557356/en/EMD-Serono-Unveils-New-MAVENCLAD%C2%AE-Four-Year-Data-Highlighting-Benefits-of-Early-Treatment-and-Sustained-Efficacy-Across-Multiple-Measures-of-Disease-Activity

+ posts

Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.